Provided by Tiger Fintech (Singapore) Pte. Ltd.

Xeris Pharmaceuticals Inc

4.82
+0.26005.70%
Post-market: 4.80-0.0200-0.41%19:47 EDT
Volume:6.61M
Turnover:31.47M
Market Cap:741.99M
PE:-12.90
High:4.90
Open:4.59
Low:4.50
Close:4.56
Loading ...

Company Profile

Company Name:
Xeris Pharmaceuticals Inc
Exchange:
NASDAQ
Establishment Date:
2005
Employees:
394
Office Location:
1375 West Fulton Street,Suite 1300,Chicago,Illinois,United States
Zip Code:
60607
Fax:
- -
Introduction:
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

Directors

Name
Position
Paul Edick
Chief Executive Officer and Chairman of the Board
Dawn Halkuff
Director
Jeffrey Sherman
Director
John H. Johnson
Director
Marla Persky
Director

Shareholders

Name
Position
Paul Edick
Chief Executive Officer and Chairman of the Board
John Shannon
President and Chief Operating Officer
Ken Johnson
Senior Vice President, Global Development and Medical Affairs
Steven M. Pieper
Chief Financial Officer
Beth Hecht
Chief Legal Officer and Corporate Secretary
Steven Prestrelski
Chief Scientific Officer